Proteomics International

Proteomics International Laboratories Ltd (ASX:PIQ) is a pioneering medical technology company operating at the forefront of predictive diagnostics and bio-anal

[Proteomics International @ProteomicsI]

Our CEO David Morris discusses women's health research in BioSpectrum Asia.

The article includes Promarker®Endo, our endometriosis blood test. It is not yet available. When available, access will be through physician referral only.

https://t.co/oLD9wOgT74

[Proteomics International @ProteomicsI]

$PIQ has announced the launch of a Share Purchase Plan (SPP), seeking to raise up to A$5 million to support the next phase of the Company's commercialisation strategy.

Live investor webinar on Wed 4 November.

#SPP and webinar registration details here:
https://t.co/llMRacdeYg

[Proteomics International @ProteomicsI]

Promarker®Endo featured in the @westaustralian, highlighting endometriosis research and insights from Professor Roger Hart.

The test is not yet available. Introduction is expected in FY27 Q3 via physician referral, subject to requirements.

Read: https://t.co/m2tnHslZQp

[Proteomics International @ProteomicsI]

PromarkerEndo featured on @9NewsPerth. Hear from patient advisory group member @Parinaz_I & CEO David Morris. Commercialisation of the test via physician referral is expected in FY27 Q3, subject to requirements.

Watch now: https://t.co/9N0Al3Pq1H https://t.co/6AytTjZPtP

[Proteomics International @ProteomicsI]

@ProteomicsI (ASX: PIQ) will commence the national rollout of Promarker®D and Promarker®Eso from 26 October, through exclusive Australian #pathology distribution partner @HealiusC.

More here: https://t.co/B5ejBkBnUC

#PIQ #Promarker

[Proteomics International @ProteomicsI]

@ProteomicsI has completed independent validation of our diagnostic blood test for endometriosis, Promarker®Endo. PIQ now targeting commercial availability in FY27 Q3.

Read the full announcement here: https://t.co/llMRacdeYg

#endometriosis #medtech

[Proteomics International @ProteomicsI]

@ProteomicsI is proud to be recognised as one of Australia’s Top Diabetes Innovators in @DiabetesAus's Grand Innovation Challenge. The Showcase Pitch Event is Tuesday 18 August 3pm in Melbourne.

Register your spot at: https://t.co/QVkJ2Yupy0

[Proteomics International @ProteomicsI]

@ProteomicsI International signs national distribution agreement with Healius for Promarker® portfolio.

Please find the full announcement here: https://t.co/CNLqI1O2BD

[Proteomics International @ProteomicsI]

We're excited to announce that @ProteomicsI International has been selected as a Finalist in the 2026 @DiabetesAus Grand Innovation Challenge!

Our project showcases Promarker®D, our predictive blood test designed to identify diabetes-related kidney disease risk before onset.

[Proteomics International @ProteomicsI]

ANNOUNCEMENT: New publication!

Our latest peer-reviewed study in PharmacoEconomics – Open shows the potential health-economic value of #PromarkerD in managing CKD in people with #Type2Diabetes.

View here: https://t.co/FfV9C1l4h0

[Proteomics International @ProteomicsI]

Congratulations to Professor Timothy Davis on being appointed an Officer of the Order of Australia (AO) in the 2026 King’s Birthday Honours for distinguished service to medicine, clinical research (diabetes) and infectious diseases.

[Proteomics International @ProteomicsI]

We are deeply saddened by the passing of Professor Ele Ferrannini, a visionary scientist who transformed the treatment of diabetes.

As a member of the Promarker®D Clinical Advisory Board, his expertise contributed to improving the prediction of chronic kidney disease.

[Proteomics International @ProteomicsI]

We're shifting focus to commercialising our diagnostic tests. With ongoing innovation, a distributor-driven rollout, and new leadership, we’re ready for growth, reimbursement, and global expansion.

View article: https://t.co/bQiuIyjbz7

[Proteomics International @ProteomicsI]

We’re pleased to see Proteomes (MDPI) publish an interview with Dr Scott Brigans, Head of Research at @urn:li:organization:2377372, discussing recent work in blood‑based diagnostics for oesophageal cancer.

https://t.co/RcvqNcv4wo

[Proteomics International @ProteomicsI]

Endometriosis affects 1 in 9 women, yet diagnosis takes years.

We're hosting an education evening for healthcare professionals on 26 March focused on practical management & triage in primary care.

Free event. CPD applicable. Webinar available.

Register: https://t.co/NETmpeBIIO

[Proteomics International @ProteomicsI]

Australia goes RED for World Kidney Day.

Landmarks across the country were illuminated RED as part of the national awareness initiative led by @KidneyHealth Australia to highlight the growing impact of chronic kidney disease.

#WorldKidneyDayAU #KHA #KidneyCodeRed

[Proteomics International @ProteomicsI]

World Kidney Day highlights the impact of chronic kidney disease in Australia.

Proteomics International has researched protein biomarkers associated with kidney disease risk, including clinical evaluation of the Promarker®D assay.

#WorldKidneyDay #KidneyCodeRed #Awareness

[Proteomics International @ProteomicsI]

Recent stories in the media have been deeply distressing for many in the endometriosis community. We acknowledge how difficult it can be to read or hear accounts of painful experiences and concerns about care, and we recognise the courage of those who have shared their stories.

[Proteomics International @ProteomicsI]

High-plex discovery is easy. Clinical translation is the challenge.

Promarker® supports biomarker validation for clinical research using targeted mass spectrometry assays, quantitative data, and ISO-accredited laboratory workflows.

Enquire here: https://t.co/SzAwE5SoL0

[Proteomics International @ProteomicsI]

We’re pleased to appoint David Morris as CEO & Managing Director of Proteomics International Laboratories Ltd (ASX: PIQ), effective 19th Jan 2026.

David brings deep global MedTech leadership as we accelerate commercialisation of the Promarker® pipeline.